Thus, these bi-transgenic FSHD-like models allow investigators to recapitulate the chronic, low-levels of DUX4 using the mild model, or investigate more severe DUX4-mediated pathology by an investigator-controlled increase in DUX4 expression using TMX. Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.